United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - streptococcus pneumoniae capsular polysaccharide protein conjugate - suspension for injection

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - streptococcus pneumoniae capsular polysaccharide protein conjugate - suspension for injection

European Union - English - EMA (European Medicines Agency)

intervacc ab - recombinant streptococcus equi protein cce, recombinant streptococcus equi protein eq85, recombinant streptococcus equi protein idee - immunologicals for equidae - horses - for the active immunisation to reduce clinical signs and the number of abscesses in acute stage of infection with s. equi.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

glaxosmithkline pharmaceutical sdn. bhd. - streptococcus pneumoniae; streptococcus pneumoniae; streptococcus pneumoniae; streptococcus pneumoniae; streptococcus pneumoniae; streptococcus pneumoniae; streptococcus pneumoniae; streptococcus pneumoniae; streptococcus pneumoniae; streptococcus pneumoniae -

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - streptococcus pneumoniae type 1 capsular polysaccharide antigen (unii: h9noi61uh1) (streptococcus pneumoniae type 1 capsular polysaccharide antigen - unii:h9noi61uh1), streptococcus pneumoniae type 2 capsular polysaccharide antigen (unii: e11p4f3x4s) (streptococcus pneumoniae type 2 capsular polysaccharide antigen - unii:e11p4f3x4s), streptococcus pneumoniae type 3 capsular polysaccharide antigen (unii: 4fvb62aff1) (streptococcus pneumoniae type 3 capsular polysaccharide antigen - unii:4fvb62aff1), strep - streptococcus pneumoniae type 1 capsular polysaccharide antigen 25 ug in 0.5 ml - pneumovax® 23 is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6b, 7f, 8, 9n, 9v, 10a, 11a, 12f, 14, 15b, 17f, 18c, 19f, 19a, 20, 22f, 23f, and 33f). pneumovax 23 is approved for use in persons 50 years of age or older and persons aged ≥2 years who are at increased risk for pneumococcal disease. pneumovax 23 will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine. do not administer pneumovax 23 to individuals with a history of anaphylactic/anaphylactoid or severe allergic reaction to any component of the vaccine. [see description (11).] risk summary all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. available human data from clinical trials of

United States - English - NLM (National Library of Medicine)

the wellness center for research and education, inc. - streptococcus viridans group (unii: nnv2379hkr) (streptococcus viridans group - unii:nnv2379hkr), chlamydia trachomatis (unii: t6ni39qu44) (chlamydia trachomatis - unii:t6ni39qu44), clostridium tetani (unii: 751e8j54vm) (clostridium tetani - unii:751e8j54vm), neisseria meningitidis (unii: v3tp2md7f3) (neisseria meningitidis - unii:v3tp2md7f3), phytolacca americana root (unii: 11e6vi8veg) (phytolacca americana root - unii:11e6vi8veg), streptococcus agalactiae (unii: 2b3763s671) (streptococcus agalactia - for temporary relief of inflammation, fever, coughing, aching, soreness, limb pain, pale skin, cold hands and feet, rash, sinus and/or throat mucus, glandular swelling, vaginal discharge, vaginal itching, burning when urinating. for tempoary relief of inflammation, fever, coughing, aching, soreness, limb pain, pale skin, cold hands and feet, rash, sinus and/or throat mucus, glandular swelling, vaginal discharge, vaginal itcdhing, burning when urinating.

United States - English - NLM (National Library of Medicine)

boiron - streptococcus pyogenes (unii: lj2lp0yl98) (streptococcus pyogenes - unii:lj2lp0yl98) - rx only* stop use and ask a doctor if symptoms persist for more than 3 days or worsen

United States - English - NLM (National Library of Medicine)

boiron - streptococcus pyogenes (unii: lj2lp0yl98) (streptococcus pyogenes - unii:lj2lp0yl98) - rx only* stop use and ask a doctor if symptoms persist for more than 3 days or worsen

United States - English - NLM (National Library of Medicine)

boiron - streptococcus pyogenes (unii: lj2lp0yl98) (streptococcus pyogenes - unii:lj2lp0yl98) - rx only* stop use and ask a doctor if symptoms persist for more than 3 days or worsen

United States - English - NLM (National Library of Medicine)

boiron - streptococcus pyogenes (unii: lj2lp0yl98) (streptococcus pyogenes - unii:lj2lp0yl98) - rx only* stop use and ask a doctor if symptoms persist for more than 3 days or worsen